Pfizer's hemophilia therapy reduces bleeding in late-stage study
May 30 (Reuters) -U.S. drugmaker Pfizer Inc PFE.N said on Tuesday late-stage study data for its experimental hemophilia therapy showed superiority to the current standard of care treatment in reducing bleeding rates in patients.
The therapy, marstacimab, met its main trial goal, demonstrating superiority to factor replacement therapies, with a 92% reduction in bleeding in patients with severe hemophilia A and moderately severe to severe hemophilia B, Pfizer said.
Hemophilia hampers the body's ability to make blood-clotting proteins, leading to prolonged bleeding following injuries or surgery, and it primarily affects males, according to government data.
The estimated prevalence in the United States is 12 cases per 100,000 males for hemophilia A and 3.7 cases per 100,000 males for hemophilia B.
The current standard of care requires regular infusion of the missing proteins.
Pfizer's once weekly marstacimab is an anti-tissue factor pathway inhibitor that could help initiate blood clotting.
Australian drugmaker CSL Ltd's CSL.AX gene therapy Hemgenix offers a long-term solution for hemophilia B patients, but is among the world's most expensive treatments.
Pfizer is developing at least two other therapies for treating hemophilia. Last year in December, the drugmaker met its main goal in a late-stage study for a hemophilia B gene therapy.
The current trial of marstacimab only tested patients who did not have any antibodies that stop the production of the blood-clotting proteins called factor VIII or factor IX.
Pfizer is also testing marstacimab in patients with those inhibitors, with data expected in late 2024.
Reporting by Vaibhav Sadhamta and Aditya Samal in Bengaluru; Editing by Shinjini Ganguli
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.